REFERENCES
- Rabe K F, Hurd S, Anzueto A, Barnes P J, Buist S A, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van W C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–555, 2007
- Agusti A, Thomas A. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006; 3: 478–481
- Celli B R, MacNee W, Agusti A G, Anzueto A, Berg B R, Buist A S, Calverley P, Chavannes N, Dillard T, Fahy B, Fein A, Heffner J, Lareau S C, Meek P, Martinez F, McNicholas W T, Muris J, Austergard E, Pauwels R, Rennard S, Rossi A, Siafakas N, Tiep B, Vestbo J, Wouters E, ZuWallack R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946
- Burrows B, Fletcher C M, Heard B E, Jones N L, Wootliff J S. 1966. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966; 1: 830–835
- Schols A M, Soeters P B, Dingemans A M, Mostert R, Frantzen P J, Wouters E F. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151–1156
- Agusti A G, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347–360
- Fabbri L M, Rabe K F. From COPD to chronic systemic inflammatory syndrome?. Lancet 2007; 370: 797–799
- Decramer M, Rennard S, Troosters T, Mapel D W, Giardino N D, Mannino D, Wouters E, Sethi S, Cooper C B. COPD as a lung disease with systemic consequences – clinical impact, mechanisms, and potential for early intervention. J COPD 2008, (In press)
- Agusti A. Systemic effects of chronic obstructive pulmonary disease:What we know and what we don't know (but should). Proc Amer Thoracic Soc 2007; 4: 522–525
- Sin D D, Lacy P, York E, Man S FP. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760–765
- Sin D D, Man S FP, Marciniuk D D, Ford G, Fitz Gerald M, Wong E, York E, Mainra R R, Ramesh W, Melenka L S, Wilde E, Cowie R L, Williams D, Gan W Q, Rousseau R. B. i. C. I. for the ABC (Advair). The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207–1214
- Pinto-Plata V, Toso J, Lee K, Bilello J, Mullerova H, De Souza M, Vessey R, Celli B. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Amer Thoracic Soc 2006; 3: 465–466
- Sims M W, Tal-Singer R W, Kierstein S, Musani A I, Beers M F, Panettieri R A, Jr., Haczku A. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008; 9: 13
- Cazzola M, MacNee W, Martinez F J, Rabe K F, Franciosi L G, Barnes P J, Brusasco V, Burge P S, Calverley P MA, Celli B R, Jones P W, Mahler D A, Make B, Miravitlles M, Page C P, Palange P, Parr P, Pistolesi M, Rennard S I, Rutten-Van Molken M PR, Stockley R, Sullivan S D, Wedzicha J A, Wouters E F, on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416–469
- Vestbo J, Anderson W, Coxson H O, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas D A, MacNee W, Silverman E K, Tal-Singer R. The E. i. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE). Eur Respir J 2008, 09031936
- Fabbri L M, Luppi F, Beghe B, Rabe K F. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204–212
- Boyd C M, Darer J, Boult C, Fried L P, Boult L, Wu A W. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294: 716–724
- Au D H. Use of β blockers in patients with COPD. Thorax 2008; 63: 296–298